Hadassah

New Lymphoma Drug, Thanks to Hadassah and Pennsylvania Physician/Scientists

Tuesday, Dec 29 2015

Nephrologist Prof. Michal Dranitzki Elhalel and Pennsylvania Pathologist Prof. Mark L. Tykocinski.

KAHR-102, a new immunotherapy drug to treat lymphoma, based on technology developed by Hadassah Medical Center Nephrologist Prof. Michal Dranitzki Elhalel and Pennsylvania Pathologist Prof. Mark L. Tykocinski, will begin clinical trials in mid-2016 at Hadassah, Tel-Hashomer, and Ichilov (Tel Aviv) medical centers.

Prof. Dranitzki Elhalel, now head of Nephrology at Hadassah, explored possible applications for the fusion protein CTLA4-Fast while a research fellow in 2000 at the University of Pennsylvania laboratory of Prof. Mark L. Tykocinski, who invented CTLA4, now known as KAHR-102. Prof. Tykocinski, then head of the Department of Pathology and Laboratory Medicine at the University of Pennsylvania, is now Dean of the Jefferson Medical School, Philadelphia, PA and Provost and Executive Vice President for Academic Affairs of the Thomas Jefferson University.

When she returned to Hadassah, Prof. Dranitzki Elhalel, with Prof. Tykocinski's encouragement,  continued to study this potential drug in her own laboratory, as well as other fusion proteins of the same class. KAHR-102, she explains,”is a fusion of portions of two naturally occurring human proteins into one chimeric protein with two functional ends. These two functional ends can bring synergistic effects, leading to highly targeted death of specific cells that can bind both sides of the protein, like malignant lymphoma cells.” She adds: “Interestingly, we found out that the resulting fusion protein has a unique structure that strongly increases its potency while conserving its specificity to the malignant lymphoma cells.”

KAHR medical Ltd., based on Prof. Tykocinski's patents, was established in 2007 by Hadasit, Hadassah’s technology transfer company. Prof. Tykocinski is Chair of the Scientific Clinical Advisory Board and Prof. Dranitzki Elhalel serves as KAHR’a Chief Scientist. Prof. Arnold Freedman, head of the Lymphoma Program at Dana Farber Cancer Institute, Boston, has recently joined KAHR’s Scientific Advisory Board.

The KAHR-102 study protocol was recently approved by the Israeli regulatory authorities, clearing the way for the clinical trial to begin mid-2016. The drug company, specializing in cancer and autoimmune disease drugs, reports that its products “form a new generation of biological drugs with great diversity and superior efficacy for the treatment of multiple cancer and autoimmune diseases.”

Comments

From: janine on February 14, 2016
can you have me? I have lymphoma,
From: janine on February 14, 2016
As a person living with lymphoma, I an excited to learn more. Can you help me?
From: Muriel on February 5, 2016
As a person living with lymphoma, I am very anxious to learn the results of the clinical trial. It sounds promising and I really hope it is effective.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Feb 14 2018

Student with MS Running the Jerusalem Marathon to Support Hadassah’s MS Program

Thanks to his physicians at the Hadassah Medical Center, Dov Guggenheim, who was diagnosed with Multiple Sclerosis (MS) in 2015, has gone from “depressed to optimistic, paralyzed to athletic, and, most important, hopeless to hopeful.”

READ MORE ›
alt_text

Wednesday, Feb 7 2018

Texas Tropical Disease Expert Meets with Hadassah Infectious Disease Specialists

Dr. Peter Jay Hotez, renowned professor in the Departments of Pediatrics and Molecular Virology and Microbiology at Houston (Texas) Baylor College of Medicine and Dean of its National School of Tropical Medicine, met with two Hadassah Medical Organization infectious disease specialists to discuss regional cooperation in fighting tropical diseases, such as the now-infamous Zika virus and leishmaniosis, which is contracted from sand flies.

READ MORE ›
alt_text

Wednesday, Feb 7 2018

Large Hadassah Study Identifies Predictor of Greater Risk of End-Stage Renal Disease

The findings of a nationwide study of over a million and a half Israeli adolescents, conducted by researchers at the Hadassah-Hebrew University Braun School of Public Health and Community Medicine, suggest that kidney disease in childhood is associated with a significantly increased risk of end-stage renal disease (ESRD) in adulthood, even if kidney function seems normal in adolescence.

READ MORE ›
alt_text

Wednesday, Feb 7 2018

Israeli Start-up’s Algorithm Predicts Which Diabetic Patients Will Suffer Kidney Dysfunction Within One Year

The Israeli start-up Medial EarlySign has created a machine-learning-based model that has proven to identify diabetic patients who are at the highest risk for experiencing renal dysfunction within one year.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More